SNPX - Synaptogenix to raise $14M through private placement of equity offering

Synaptogenix (SNPX) formerly Neurotrope Bioscience, to raise ~$14M in a private placement of common stock at $1.50/share, one-year warrants to purchase an equal number of common stock at $2.1275 and five-year warrants to purchase an equal number of common stock at $1.725 per share. Proceeds will be used to complete its current Phase 2 clinical trial for Alzheimer's disease, possible additional future AD trials, the use of Bryostatin for other possible indications, and for general corporate purposes.

For further details see:

Synaptogenix to raise $14M through private placement of equity offering